Laser Ablation a Salvage Treatment for Obstructive Benign Prostatic Hyperplasia

TPLA of the prostate represents a promising minimally invasive treatment modality for men experiencing LUTS secondary to BPH. This technique offers a potentially attractive alternative to traditional surgical interventions, particularly given the growing interest in less invasive procedures. The current literature focuses on evaluating the effectiveness of TPLA in improving urodynamic parameters (specifically maximum urinary flow rate (Qmax) and post-void residual volume (PVR), alleviating LUTS, and preserving sexual and ejaculatory function, as well as surgical complications.

In a recent systematic review, which included 6 studies, studies consistently reported statistically significant improvements from baseline in Qmax, PVR, and IPSS scores (International Prostate Symptom Score) at all measured time points. Furthermore, three of the studies demonstrated that TPLA did not negatively impact sexual function, showing no significant changes in IIEF-6 scores (International Index of Erectile Function) and, in some cases, statistically significant improvements in MSHQ-EjD scores (Male Sexual Health Questionnaire) at various follow-up intervals, Low complication rates were observed across all studies. Pooled analysis of the available data revealed clinically meaningful improvements in both voiding and sexual function outcomes at 1-, 3-, and 6-, and 12-months post-treatment, when compared to baseline values.

While the preliminary findings from these pilot studies suggest that TPLA may be a valuable treatment option for BPH, further research is warranted. Specifically, there is a lack of data demonstrating the efficacy of TPLA as a salvage option, where other MIST options failed.

Inclusion criteria

• Men > 40 years old
• History of Minimally invasive BPH procedure within the last 5 years.
• IPSS >= 12
• Prostate Volume 30 - 80 gr as assessed by CT, MRI or TRUS.
• PSA <4 or for patients with PSA 4-10 evaluation has been performed to rule out prostate cancer using biopsy, MRI, biomarker, or surgeon judgement. Labs within 1 year of study initiation
• PVR > 150cc or reduced flow on uroflow likely due to obstruction based on clinical judgement
• IIEF-6>or =10 without medication

Exclusion criteria

• Indwelling catheter or intermittent catheterization
• History of urethral strictures
• Previous diagnosis of Prostate cancer
• Active UTI or prostatitis
• Hypoactive detrusor function
• Neurogenic bladder (secondary to stroke, Multiple Sclerosis, Parkinson's disease, Spinal cord injury)
• Ejaculatory dysfunction (retrograde ejaculation, anorgasmia or anejaculation)
• Prior traditional BPH surgery (TURP, PVP, Aquablation, HOLEP, SP)
• Presence of obstructive median lobe
• Moderate to severe or severe ED based on IIEF-6/SHIM (SHIM of 10)
• Peyronie's disease